U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H20N4O6S
Molecular Weight 348.377
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RELEBACTAM ANHYDROUS

SMILES

C1C[C@@]([H])(C(=NC2CCNCC2)O)N3C[C@]1([H])N(C3=O)OS(=O)(=O)O

InChI

InChIKey=SMOBCLHAZXOKDQ-ZJUUUORDSA-N
InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1

HIDE SMILES / InChI
Relebactum sodium (MK-7655) is a piperidine analog 3 that inhibits class A and C β-lactamases (in vitro). It is being investigated for use in treatment of infectious diseases, such as treatment of gram-negative bacterial infections. Its potential as an alternative to existing medicines in the treatment of drug-resistant bacterial infections is being studied. Clinical trials have been conducted and are still ongoing to evaluate the efficacy and safety of relebactum sodium in treatment of intra-abdominal infections, urinary tract infections (such as pyelonephritis), hospital-acquired and ventilator-associated bacterial pneumonias, and gram-negative bacterial infections.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: 1.6834582E7
Gene Symbol: blaKPC-2
210.0 nM [IC50]
Target ID: 878149.0
Gene Symbol: ampC
410.0 nM [IC50]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
64 μM
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: IMIPENEM
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
427.3 μM × h
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: IMIPENEM
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
396 μM × h
1150 mg single, intravenous
dose: 1150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.97 μM × h
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
81.8 μM × h
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.2 h
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: IMIPENEM
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.78 h
1150 mg single, intravenous
dose: 1150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.39 h
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.63 h
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
78%
250 mg 4 times / day multiple, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: IMIPENEM
RELEBACTAM ANHYDROUS plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, 24 to 42 years
n = 17
Health Status: healthy
Age Group: 24 to 42 years
Sex: M+F
Population Size: 17
Sources:
Disc. AE: Diarrhea, Nausea...
Other AEs: Fatigue, Blood creatinine increased...
AEs leading to
discontinuation/dose reduction:
Diarrhea (grade 1, 5.9%)
Nausea (grade 2, 5.9%)
Vomiting (grade 2, 5.9%)
Other AEs:
Fatigue (grade 1, 5.9%)
Blood creatinine increased (grade 1, 5.9%)
Sources:
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 49.7 years
n = 87
Health Status: unhealthy
Condition: Complicated Intra-Abdominal Infection
Age Group: mean age 49.7 years
Sex: M+F
Population Size: 87
Sources:
Disc. AE: Decreased creatinine clearance...
Other AEs: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Decreased creatinine clearance (1.1%)
Other AEs:
Diarrhea (>5)
Nausea (>5)
Vomiting (>5)
Sources:
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Other AEs: Anemia, Diarrhea...
Other AEs:
Anemia (1%)
Diarrhea (6%)
Nausea (6%)
Vomiting (3%)
Infusion site phlebitis (2%)
Pyrexia (2%)
Alanine aminotransferase increased (3%)
Aspartate aminotransferase increased (3%)
Lipase increased (1%)
Blood creatinine increased (<1%)
Headache (4%)
Central nervous system disorder NOS (1%)
Hypertension (2%)
Sources:
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Other AEs: Upper abdominal pain, Diarrhea...
Other AEs:
Upper abdominal pain (grade 1-2, 16.7%)
Diarrhea (grade 1-2, 16.7%)
Infusion site erythema (grade 1-2, 50%)
Infusion site pain (grade 1-2, 50%)
Infusion site pruritus (grade 1-2, 16.7%)
Infusion site swelling (grade 1-2, 16.7%)
Dizziness (grade 1-2, 16.7%)
Headache (grade 1-2, 16.7%)
Sources:
1150 mg 1 times / day single, intravenous
MTD|Highest studied dose
Dose: 1150 mg, 1 times / day
Route: intravenous
Route: single
Dose: 1150 mg, 1 times / day
Sources:
healthy, median age 28.5 years
n = 6
Other AEs: Feeling of body temperature change...
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Other AEs: Diarrhea, ALT increased...
Other AEs:
Diarrhea (grade 1-2, 8.3%)
ALT increased (grade 1-2, 4.2%)
Discoloration tongue (grade 1-2, 33.3%)
Discoloration tooth (grade 1-2, 4.2%)
Asthenia (grade 1-2, 4.2%)
Feeling hot (grade 1-2, 4.2%)
Feeling of body temperature change (grade 1-2, 4.2%)
Infusion site erythema (grade 1-2, 37.5%)
Infusion site pain (grade 1-2, 25%)
Infusion site swelling (grade 1-2, 20.8%)
AST increased (grade 1-2, 4.2%)
Decreased appetite (grade 1-2, 4.2%)
Arthralgia (grade 1-2, 4.2%)
Muscle twitching (grade 1-2, 4.2%)
Myalgia (grade 1-2, 4.2%)
Headache (grade 1-2, 12.5%)
Rash (grade 1-2, 4.2%)
Sources:
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Other AEs: Thrombocytosis, Abdominal pain...
Other AEs:
Thrombocytosis (1%)
Abdominal pain (2%)
Diarrhoea (2%)
Nausea (6.1%)
Bacteriuria (2%)
ALT increased (1%)
AST increased (2%)
Bacterial test positive (1%)
Blood creatinine increased (1%)
White blood cells urine positive (1%)
Dysgeusia (2%)
Headache (3%)
Hypertension (2%)
Transaminases increased (1%)
Sources:
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Disc. AE: Diarrhoea, Rash...
Other AEs: Thrombocytosis, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Diarrhoea (1%)
Rash (1%)
Other AEs:
Thrombocytosis (2%)
Diarrhoea (5.1%)
Nausea (4%)
Pyrexia (2%)
Bacteriuria (1%)
Influenza (2%)
ALT increased (2%)
AST increased (1%)
Bacterial test positive (1%)
Protein urine present (1%)
Red blood cells urine positive (1%)
White blood cells urine positive (1%)
Headache (7.1%)
Hypertension (3%)
Transaminases increased (1%)
Sources:
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 60 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 60 years
Sex: M+F
Population Size: 99
Sources:
Disc. AE: Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood creatinine increased grade 1, 5.9%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, 24 to 42 years
n = 17
Health Status: healthy
Age Group: 24 to 42 years
Sex: M+F
Population Size: 17
Sources:
Fatigue grade 1, 5.9%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, 24 to 42 years
n = 17
Health Status: healthy
Age Group: 24 to 42 years
Sex: M+F
Population Size: 17
Sources:
Diarrhea grade 1, 5.9%
Disc. AE
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, 24 to 42 years
n = 17
Health Status: healthy
Age Group: 24 to 42 years
Sex: M+F
Population Size: 17
Sources:
Nausea grade 2, 5.9%
Disc. AE
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, 24 to 42 years
n = 17
Health Status: healthy
Age Group: 24 to 42 years
Sex: M+F
Population Size: 17
Sources:
Vomiting grade 2, 5.9%
Disc. AE
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, 24 to 42 years
n = 17
Health Status: healthy
Age Group: 24 to 42 years
Sex: M+F
Population Size: 17
Sources:
Decreased creatinine clearance 1.1%
Disc. AE
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 49.7 years
n = 87
Health Status: unhealthy
Condition: Complicated Intra-Abdominal Infection
Age Group: mean age 49.7 years
Sex: M+F
Population Size: 87
Sources:
Diarrhea >5
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 49.7 years
n = 87
Health Status: unhealthy
Condition: Complicated Intra-Abdominal Infection
Age Group: mean age 49.7 years
Sex: M+F
Population Size: 87
Sources:
Nausea >5
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 49.7 years
n = 87
Health Status: unhealthy
Condition: Complicated Intra-Abdominal Infection
Age Group: mean age 49.7 years
Sex: M+F
Population Size: 87
Sources:
Vomiting >5
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 49.7 years
n = 87
Health Status: unhealthy
Condition: Complicated Intra-Abdominal Infection
Age Group: mean age 49.7 years
Sex: M+F
Population Size: 87
Sources:
Anemia 1%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Central nervous system disorder NOS 1%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Lipase increased 1%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Hypertension 2%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Infusion site phlebitis 2%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Pyrexia 2%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Alanine aminotransferase increased 3%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Aspartate aminotransferase increased 3%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Vomiting 3%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Headache 4%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Diarrhea 6%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Nausea 6%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Blood creatinine increased <1%
250 mg 4 times / day multiple, intravenous
Recommended
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, mean age 56.4 years and 49.1 years
n = 216
Health Status: unhealthy
Condition: Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection
Age Group: mean age 56.4 years and 49.1 years
Sex: M+F
Population Size: 216
Sources:
Diarrhea grade 1-2, 16.7%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Dizziness grade 1-2, 16.7%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Headache grade 1-2, 16.7%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Infusion site pruritus grade 1-2, 16.7%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Infusion site swelling grade 1-2, 16.7%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Upper abdominal pain grade 1-2, 16.7%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Infusion site erythema grade 1-2, 50%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Infusion site pain grade 1-2, 50%
625 mg 4 times / day multiple, intravenous
MTD
Dose: 625 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 625 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 27 years
n = 6
Feeling of body temperature change grade 1-2, 16.7%
1150 mg 1 times / day single, intravenous
MTD|Highest studied dose
Dose: 1150 mg, 1 times / day
Route: intravenous
Route: single
Dose: 1150 mg, 1 times / day
Sources:
healthy, median age 28.5 years
n = 6
Headache grade 1-2, 12.5%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Infusion site swelling grade 1-2, 20.8%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Infusion site pain grade 1-2, 25%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Discoloration tongue grade 1-2, 33.3%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Infusion site erythema grade 1-2, 37.5%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
ALT increased grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
AST increased grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Arthralgia grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Asthenia grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Decreased appetite grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Discoloration tooth grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Feeling hot grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Feeling of body temperature change grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Muscle twitching grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Myalgia grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Rash grade 1-2, 4.2%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
Diarrhea grade 1-2, 8.3%
500 mg 4 times / day multiple, intravenous
MTD
Dose: 500 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 500 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
healthy, median age 53.3
n = 24
ALT increased 1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Bacterial test positive 1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Blood creatinine increased 1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Thrombocytosis 1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Transaminases increased 1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
White blood cells urine positive 1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
AST increased 2%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Abdominal pain 2%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Bacteriuria 2%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Diarrhoea 2%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Dysgeusia 2%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Hypertension 2%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Headache 3%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Nausea 6.1%
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
AST increased 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Bacterial test positive 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Bacteriuria 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Protein urine present 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Red blood cells urine positive 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Transaminases increased 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
White blood cells urine positive 1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Diarrhoea 1%
Disc. AE
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Rash 1%
Disc. AE
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
ALT increased 2%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Influenza 2%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Pyrexia 2%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Thrombocytosis 2%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Hypertension 3%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Nausea 4%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Diarrhoea 5.1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Headache 7.1%
250 mg 4 times / day multiple, intravenous
Dose: 250 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 250 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 58 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 58 years
Sex: M+F
Population Size: 99
Sources:
Nausea 1%
Disc. AE
125 mg 4 times / day multiple, intravenous
Dose: 125 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 125 mg, 4 times / day
Co-administed with::
imipenem(500 mg; IV; 4 per day)
cilastatin(500 mg; IV; 4 per day)
Sources:
unhealthy, median age 60 years
n = 99
Health Status: unhealthy
Condition: complicated urinary tract infections
Age Group: median age 60 years
Sex: M+F
Population Size: 99
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no
no
no
no
no
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
yes
yes
yes
yes
Tox targets
Name Type Language
RELEBACTAM ANHYDROUS
Common Name English
RELEBACTAM [WHO-DD]
Common Name English
RELEBACTAM [INN]
Common Name English
MK-7655
Code English
(-)-RELEBACTAM ANHYDROUS
Common Name English
SULFURIC ACID MONO-((2S,5R)-7-OXO-2-(PIPERIDIN-4-YLCARBAMOYL)-1,6-DIAZA-BICYCLO(3.2.1)OCT-6-YL) ESTER
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C258
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
Code System Code Type Description
INN
10027
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY
FDA UNII
1OQF7TT3PF
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY
EVMPD
SUB184909
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY
NCI_THESAURUS
C152175
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY
PUBCHEM
44129647
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY
CAS
1174018-99-5
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY
RXCUI
2268500
Created by admin on Sat Jun 26 03:17:23 UTC 2021 , Edited by admin on Sat Jun 26 03:17:23 UTC 2021
PRIMARY